StockStory picks Pfizer as a healthcare stock to watch, flags Biogen and UFP Technologies as sells

Industry
โดย StockStory·Read original
Summary · why it matters

StockStory highlights Pfizer as a healthcare stock with solid fundamentals, while advising caution on Biogen and UFP Technologies. Pfizer, with $63.32 billion in revenue, benefits from scale and improved operating efficiency, posting an 18.1% return on invested capital. Biogen faces a 4.6% annual revenue decline over five years and shrinking profitability amid rising competition. UFP Technologies, with a modest $608.9 million revenue base, saw flat adjusted operating margins over two years, indicating limited fixed-cost leverage.

Impact on stocks 3

Biotech & Genomic Medicine± Mixed · 3 stocks
Biogen Inc
BIIB
▼ NegativeCompetitionrelevance

Biogen faces a 4.6% annual revenue decline over five years and shrinking profitability amid rising competition.

Pfizer Inc
PFE
▲ PositiveCapitalrelevance

Pfizer has solid fundamentals, scale, improved operating efficiency, and an 18.1% return on invested capital.

UFP Technologies Inc
UFPT
▼ NegativeCapitalrelevance

UFP Technologies has a modest revenue base and flat adjusted operating margins over two years, indicating limited fixed-cost leverage.

© 2026 MarketDXNews